X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA CIPLA ALEMBIC PHARMA/
CIPLA
 
P/E (TTM) x 28.7 44.7 64.3% View Chart
P/BV x 6.6 3.8 171.1% View Chart
Dividend Yield % 0.7 0.3 214.4%  

Financials

 ALEMBIC PHARMA   CIPLA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
CIPLA
Mar-17
ALEMBIC PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs792622 127.3%   
Low Rs443458 96.7%   
Sales per share (Unadj.) Rs167.0181.9 91.8%  
Earnings per share (Unadj.) Rs38.212.9 296.5%  
Cash flow per share (Unadj.) Rs42.029.3 143.2%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.60.4 175.0%  
Book value per share (Unadj.) Rs84.9155.7 54.5%  
Shares outstanding (eoy) m188.52804.51 23.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.73.0 124.5%   
Avg P/E ratio x16.242.0 38.5%  
P/CF ratio (eoy) x14.718.4 79.8%  
Price / Book Value ratio x7.33.5 209.6%  
Dividend payout %10.515.5 67.5%   
Avg Mkt Cap Rs m116,383434,516 26.8%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m4,21426,338 16.0%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m31,487146,302 21.5%  
Other income Rs m552,287 2.4%   
Total revenues Rs m31,542148,589 21.2%   
Gross profit Rs m10,06024,758 40.6%  
Depreciation Rs m72213,229 5.5%   
Interest Rs m371,594 2.3%   
Profit before tax Rs m9,35612,222 76.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2-70 2.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1601,798 120.2%   
Profit after tax Rs m7,19410,354 69.5%  
Gross profit margin %31.916.9 188.8%  
Effective tax rate %23.114.7 157.0%   
Net profit margin %22.87.1 322.8%  
BALANCE SHEET DATA
Current assets Rs m15,06687,370 17.2%   
Current liabilities Rs m7,67433,081 23.2%   
Net working cap to sales %23.537.1 63.3%  
Current ratio x2.02.6 74.3%  
Inventory Days Days6787 77.0%  
Debtors Days Days4162 65.2%  
Net fixed assets Rs m8,237111,567 7.4%   
Share capital Rs m3771,609 23.4%   
"Free" reserves Rs m15,416123,645 12.5%   
Net worth Rs m16,005125,254 12.8%   
Long term debt Rs m036,454 0.0%   
Total assets Rs m24,594209,532 11.7%  
Interest coverage x255.28.7 2,944.5%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.30.7 183.4%   
Return on assets %29.45.7 515.6%  
Return on equity %44.98.3 543.7%  
Return on capital %58.78.5 690.3%  
Exports to sales %55.734.2 162.9%   
Imports to sales %10.48.3 125.0%   
Exports (fob) Rs m17,55150,050 35.1%   
Imports (cif) Rs m3,28312,203 26.9%   
Fx inflow Rs m17,81151,066 34.9%   
Fx outflow Rs m5,31817,678 30.1%   
Net fx Rs m12,49333,388 37.4%   
CASH FLOW
From Operations Rs m9,30423,824 39.1%  
From Investments Rs m-3,105-13,127 23.7%  
From Financial Activity Rs m-1,959-13,239 14.8%  
Net Cashflow Rs m4,240-2,478 -171.1%  

Share Holding

Indian Promoters % 74.1 16.0 463.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 2.9 12.2 23.8%  
FIIs % 9.1 23.7 38.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 13.9 26.2 53.1%  
Shareholders   49,328 161,166 30.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  STRIDES SHASUN LTD  FDC LTD.  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 21, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - PIRAMAL ENTERPRISES COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS